Search the Newsreel

CSTL (CSTL) files notice to sell 24,908 common shares on NASDAQ

A holder of CSTL common stock has filed a notice of intent to sell up to 24,908 shares on NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services. The indicated aggregate market value of these shares is $741,493.72, and they originated from restricted …

Is Biohaven’s Narrowing Losses and AI Board Hire Altering The Investment Case For Biohaven (BHVN)?

Biohaven Ltd. reported narrowing losses in Q2 2026, with a net loss of US$137.31 million, and appointed AI-focused investor John Yetimoglu to its Board. Despite these developments, the company still faces significant financial risk due to zero revenue, heavy ongoing losses, and a short …

Dino Rossi Sells 25,000 Shares of Krystal Biotech (NASDAQ:KRYS) Stock

Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?

On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases. Under the agreement, AbCellera will leverage its proprietary TCE platform to lead discovery, while Vertex will …

BioXcel Therapeutics (BTAI) files Form 3 for new director Susan E. Atkins

BioXcel Therapeutics, Inc. (BTAI) has filed a Form 3 to report the initial beneficial ownership for its new director, Susan E. Atkins. This filing indicates her position as a director but does not list any equity transactions or current holdings. The document also notes …

BioXcel Therapeutics (BTAI) director receives option grant for 17,000 shares

BioXcel Therapeutics director Susan E. Atkins was granted stock options for 17,000 shares of common stock on August 12, 2026, with an exercise price of $1.06 per share and an expiration date of August 12, 2036. The options will vest over three years, with …

Assembly Biosciences (ASMB) Stock Jumps As Losses Shrink And Revenue Builds

Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?

Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology. On July 20, Biohaven announced a clinical supply agreement with Regeneron to evaluate the combination of BHV-1530 and Regeneron's cemiplimab (Libtayo) in patients with solid tumors. …

Helix BioPharma Reshapes Board to Align with Oncology Growth Strategy

MCDONALDS CORP (MCD) president Anderson Skye details options, PRSUs and stock

Valion Bio (OTC: VBIO) faces going concern risk and Nasdaq bid price warning

Valion Bio, Inc. (OTC: VBIO) has reported significant financial concerns, including a net loss of $13.3 million for the first six months of 2026 and an accumulated deficit of $66.5 million, raising substantial doubt about its ability to continue as a going concern. The …

BioNexus Gene Lab Corp (BGLC) grants CEO 338,709 fully vested shares

BioNexus Gene Lab Corp (BGLC) announced that its CEO and director, Tan Lee Su-Leng, received a fully vested stock award of 338,709 common shares. These shares, granted under the company's 2025 Equity Incentive Plan for completed services, were valued at $1.55 per share based …

BioNexus Gene Lab Corp (BGLC) director receives 32,258-share equity award

BioNexus Gene Lab Corp director Bin Abdul Hamid Muhammad Azrul received a fully vested equity award of 32,258 common shares on August 13, 2026. The award, valued at $1.55 per share, was granted under the company’s 2025 Equity Incentive Plan for completed services, with …

BioNexus Gene Lab Corp (BGLC) director granted 16,129-share fully vested stock award

BioNexus Gene Lab Corp (BGLC) director Low Jook Yuen received a fully vested stock award of 16,129 shares of common stock on August 13, 2026, for services rendered. This equity compensation, granted under the company's 2025 Equity Incentive Plan, had no cash consideration and …

Valion Bio, Inc. Q2 2026: Net loss $7.1M, EPS $(2.17) — 10-Q Summary

Valion Bio, Inc. reported a significant widening of its net loss in Q2 2026 to $7.1M, up from $1.93M in Q2 2025, with diluted loss per share at $(2.17). The company recorded no revenue from continuing operations. Despite financial losses, Valion Bio highlighted progress …

Twist Bioscience Corp (TWST) Stock Down 5.4% but Still Overvalued -- GF Score: 69/100

Twist Bioscience Corp (TWST) shares dropped by 5.4% to $118.57, yet the stock is considered 126.4% overvalued compared to its GF Value™ of $52.38. Despite a strong growth rank of 10/10, the company's profitability and valuation ranks are low, coupled with significant insider selling …

What's Going On With Cannara Biotech Inc. Stock Friday?

Valion Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Satellos Bioscience Sets Up US$50 Million U.S. At-the-Market Share Sales Facility

Belite Bio (BLTE) Could Be 21% Below Fair Value As FDA Priority Review Lands

Belite Bio (BLTE) is currently undervalued by 21% according to Simply Wall St. following the FDA's acceptance of its New Drug Application for tinlarebant with Priority Review. Despite a recent one-day dip, the stock has shown strong momentum over the last month and year, …

Perceptive Advisors group reports 9.1% Nautilus (NAUT) ownership in updated 13D/A

Perceptive Advisors and its related entities have filed an updated 13D/A, disclosing a 9.1% beneficial ownership in Nautilus Biotechnology, Inc. (NAUT), totaling 11,634,211 shares. This ownership is primarily held by Perceptive Life Sciences Master Fund, Ltd. and C2 Life Sciences LLC, with Perceptive Advisors …

Annovis Bio (NYSE:ANVS) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Annovis Bio reported a Q2 2026 EPS of $(0.40), exceeding the analyst estimate of $(0.45), despite widening its net loss to $14.8 million primarily due to a 131% increase in R&D expenses. The company achieved full enrollment of 850 patients in its pivotal Phase …

Helix Biopharma Corp. Announces Board Composition Changes

Swedish Orphan Biovitrum (OM:SOBI) Stock Looks Strong On Returns But Fully Priced On Earnings

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Swedish Orphan Biovitrum has delivered a strong share price run over the past five years, yet its current valuation checks lean expensive rather …

Vor Biopharma (VOR) sees Venrock-led group report 9.99% ownership stake

A Venrock-led group, including Venrock Healthcare Capital and individuals Nimish Shah and Bong Koh, has reported a beneficial ownership stake of 9.99% in Vor Biopharma Inc. (VOR). This stake comprises 5,676,370 shares of common stock, including Pre-Funded Warrants, as of June 30, 2026. A …

Perceptive Advisors discloses 7.3% SAB Biotherapeutics (SABS) stake via Master Fund

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a beneficial ownership of 7.3% in SAB Biotherapeutics (SABS). The Master Fund directly holds 6,627,501 shares, representing this percentage based on 90,986,368 shares outstanding as of August 3, 2026. All …

Sutro Biopharma (STRO): Perceptive Advisors reports 7.9% beneficial stake

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a beneficial ownership of 7.9% of Sutro Biopharma's common stock, totaling 1,304,846 shares. This ownership is based on 16,572,171 shares outstanding as of August 7, 2026. The reporting persons have …

Inhibrx Biosciences (INBX) holders disclose 1.49M-share, 9.99% position

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a beneficial ownership of 1,489,443 shares of Inhibrx Biosciences, Inc. (INBX) common stock, representing 9.99% of the class. This stake includes common shares and pre-funded warrants, with the exercise of …

Krystal Biotech, Inc. SEC Filing (Aug 14, 2026)

This article reports on a Form 144 SEC filing by Krystal Biotech, Inc. (KRYS) on August 14, 2026. The filing indicates a proposed sale of 25,000 shares of common stock with an aggregate market value of $8,306,750, acquired from the public market on September …

Palisade Bio (PALI): Commodore Capital group now reports 0.0% beneficial ownership

Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz have filed an amended Schedule 13G/A, reporting 0.0% beneficial ownership of Palisade Bio (PALI) common stock. The group indicates they hold 0.00 shares, representing 0.0% of the class, with no sole …

Moleculin Biotech (NASDAQ: MBRX) seeks reverse split and plan changes at 2026 meeting

Moleculin Biotech (NASDAQ: MBRX) is holding its 2026 annual shareholder meeting on October 9, 2026, where key proposals include electing directors, ratifying the independent auditor, and approving an amendment to the 2024 Equity Incentive Plan to increase authorized shares. Shareholders will also vote on …

LeonaBio Q2 Results: EPS beats estimate, losses narrow 55% YoY

Spruce Biosciences (SPRB): ADAR1, Schneeberger disclose 2.5% beneficial stake

ADAR1 Capital Management, LLC and Daniel Schneeberger have disclosed a 2.5% beneficial ownership stake in Spruce Biosciences, Inc. (SPRB) through a SCHEDULE 13G/A filing. This stake, totaling 67,717 shares, is held across various managed accounts, with both parties exercising shared voting and dispositive power. …

Rallybio Corporation (RLYB) holders report 3.56% stake in Schedule 13G/A

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 3.56% in Rallybio Corporation's common stock as of June 30, 2026. This stake amounts to 188,422 shares, over which the group holds shared voting and shared …

TYRA Biosciences (TYRA) holder reports 3.55M-share, 6% beneficial stake

RA Capital discloses 6.2% BioCryst (BCRX) holding of 15.8M shares

RA Capital Management, L.P. and its affiliated entities have reported a passive ownership stake of 6.2% in BioCryst Pharmaceuticals, Inc. This holding, as of June 30, 2026, comprises 15,827,186 shares of common stock, with RA Capital Healthcare Fund, L.P. directly owning these shares. The …